secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001213900-24-075008
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix faces Nasdaq delisting risk; must meet initial listing criteria including $4.00 minimum bid price
--------------------------------------------------------------------------------

- Nasdaq ruled Proteomedix AG acquisition triggers Change of Control; must satisfy initial listing rules including $4.00 minimum bid price.
- Company has until Sept 16, 2024 to regain Bid Price Rule compliance ($1.00 close for 10 days); extension for stockholders' equity runs to Nov 4, 2024.
- Board proposes reverse stock split (1-for-30 to 1-for-60) to boost per-share price and meet Nasdaq minimum price and equity requirements.
- Failure to comply could lead to delisting; common stock would trade OTC, materially reducing liquidity and capital access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024075008/0001213900-24-075008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390024075008/ea0213181-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-075008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer